How Paxlovid Approval May Influence China's Pandemic Policies
New Focus on Treatments Not Vaccines?
In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers.
